COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Fundamental Risk Analysis including financial ratios, debt levels, liquidity, and sustainability metrics. Compare against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Fundamental Risk Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.

Debt-to-Equity Ratio

0.11

Decreased from previous period

D/E ratio at 50-90% of Medical - Pharmaceuticals median of 0.14. Peter Lynch would verify if this conservative capital structure supports growth opportunities.

Net Debt-to-EBITDA

-0.67

Decreased from previous period

Net cash position versus Medical - Pharmaceuticals median net debt of 1.19. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.

Interest Coverage Ratio

355.26

Increased from previous period

Coverage of 355.26 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.

Current Ratio

0.60

Increased from previous period

Current ratio below 50% of Medical - Pharmaceuticals median of 3.29. Michael Burry would check for immediate refinancing needs.

Intangibles-to-Total-Assets Ratio

0.10%

Increased from previous period

Intangibles less than half the Medical - Pharmaceuticals median of 2.68%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.

Select Chart Metric:

3349.T Fundamental Risk Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Debt-to-Equity Ratio

0.11

Decreased from previous period

D/E ratio at 50-90% of Medical - Pharmaceuticals median of 0.14. Peter Lynch would verify if this conservative capital structure supports growth opportunities.

Net Debt-to-EBITDA

-0.67

Decreased from previous period

Net cash position versus Medical - Pharmaceuticals median net debt of 1.19. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.

Interest Coverage Ratio

355.26

Increased from previous period

Coverage of 355.26 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.

Current Ratio

0.60

Increased from previous period

Current ratio below 50% of Medical - Pharmaceuticals median of 3.29. Michael Burry would check for immediate refinancing needs.

Intangibles-to-Total-Assets Ratio

0.10%

Increased from previous period

Intangibles less than half the Medical - Pharmaceuticals median of 2.68%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.

Select Chart Metric: